RNA transfection

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Retrieved on: 
Thursday, December 22, 2022
Clinical trial, Mainland China, Vaccine, RNA transfection, Taiwan Commercial Office in Tripoli, Vaccination, COVID-19, COVID-19 vaccine, BNTX, R, Fosun Pharma, SAR, Omicron, BioNTech, COVID, Motor vehicle

The delivery contains both the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine and the monovalent COVID-19 vaccine.

Key Points: 
  • The delivery contains both the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine and the monovalent COVID-19 vaccine.
  • “We thank the Chinese and the German governments for their joint efforts and continuous support in helping us supply German expatriates living in China with our mono- and Omicron BA.4/BA.5-adpated bivalent mRNA COVID-19 vaccines,” said Sean Marett, Chief Business and Commercial Officer at BioNTech.
  • With the guidance and support of the relevant national authorities, the R&D and clinical trial of our mRNA-based COVID-19 vaccine in China have been executed rapidly.
  • We are glad to be working with BioNTech to provide vaccination to German expatriates living on the Chinese Mainland, which is another milestone in our global collaboration in fighting the COVID pandemic.”
    The doses are expected to be available in Beijing, Shanghai, Guangzhou, Shenyang and Chengdu.

Update on First BioNTainer for African-based mRNA Manufacturing Facility

Retrieved on: 
Wednesday, December 21, 2022
Tuberculosis, RNA transfection, Malaria, Vaccine, African Union, BNTX, BioNTech, Union

MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable mRNA vaccine production in Africa.

Key Points: 
  • MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable mRNA vaccine production in Africa.
  • In parallel, BioNTech continues to develop and build its state-of-the-art manufacturing facility in Kigali, Rwanda, following the groundbreaking in June 2022 .
  • The facility will be housing the first BioNTainers and is expected to become a node in a decentralized and robust end-to-end manufacturing network in Africa.
  • In addition, BioNTech is advancing mRNA-based vaccine candidates to address malaria and tuberculosis, based on the company’s mRNA platform.

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Retrieved on: 
Wednesday, December 21, 2022
Ageing, Invention, RNA transfection, University of Pennsylvania, Research, Distress, HIV, Glycoprotein, Global health, Risk, BNTX, Infection, Meningitis, Herpes simplex virus, World Health Organization, HSV epigenetics, Safety, Penn, University, BioNTech, IND, Immunity, HSV, History, HSV-2, Pharmaceutical industry, Vaccine

The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.

Key Points: 
  • The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.
  • Editor’s Note: The University of Pennsylvania has licensed some intellectual property related to the BNT163 vaccine candidate to BioNTech.
  • The University of Pennsylvania receives sponsored research funding from BioNTech related to preclinical development of the BNT163 vaccine candidate.
  • As inventors of certain intellectual property related to the BNT163 vaccine candidate, some of the scientists involved in the preclinical development of the candidate along with Penn, may receive additional financial benefits under the BioNTech license in the future.

Sunshine Biopharma’s Annual Letter to Shareholders

Retrieved on: 
Tuesday, December 20, 2022
Liver cancer, LNP, Mouse, Ovary, Christmas, RNA transfection, Breast, Sunlight, Acquisition, Patient, Letter, Parallel, Exercise, University, Culture, New Year, Pharmaceutical industry, Management, Security (finance), Vaccine

Dear Fellow Sunshine Biopharma Shareholders,

Key Points: 
  • Dear Fellow Sunshine Biopharma Shareholders,
    On behalf of Sunshine’s Board of Directors, our senior management team, and employees, we are delighted to have you as our shareholders and as valued stakeholders of our corporate family.
  • I am writing this letter to provide you with some of the important developments that have occurred at Sunshine over this past year and some insights into what we see ahead.
  • 2022 has been a transformative year for the Company despite some challenging headwinds with the economy and financial markets.
  • On behalf of Sunshine Biopharma and our more than 40 employees, I would like to thank all of our shareholders and supporters.

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Retrieved on: 
Tuesday, December 20, 2022
Cancer, RNA transfection, Sherbrooke, Biomarker, Colorectal cancer, Gene expression, Patient, CRC, Conditional sentence, Medical imaging

Currently, Mainz is commercializing ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) across Europe and in select international territories.

Key Points: 
  • Currently, Mainz is commercializing ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) across Europe and in select international territories.
  • ColoFuture/eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC.
  • The five mRNA targets chosen by Mainz Biomed provided the greatest sensitivity and specificity of detection (Herring et al.
  • Mainz expects to complete enrollment for the eAArly DETECT in Q1 2023 and targets reporting topline results in 1H 2023.

Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Protein, Biotechnology, RNA transfection, Indiana University, Associate degree, Gene, DNA, CCO, Academic Structure of Indiana University (Bloomington), NYSE, Entrepreneurship, Danaher Corporation, DHR, Cell, Marketing, ACT Biotech Inc, Management, Vaccine, Science, Biology

Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023.

Key Points: 
  • Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023.
  • Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica’s commercial efforts to drive global sales and new business growth.
  • “We are pleased to welcome Ms. Thompson-Webb to Virica’s executive team,” said Dr. Jean-Simon Diallo, CEO and Co-Founder at Virica.
  • Prior to that, Ms. Thompson-Webb was General Manager, Global Commercial for Cell and Gene Therapy at Cytiva, part of Danaher Corporation ( $NYSE: DHR ).

Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines

Retrieved on: 
Thursday, January 5, 2023
Veterinary, Research, Infectious Diseases, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, LNP Media Group, BioRxiv, RNA transfection, Cornell University College of Veterinary Medicine, Applied Biosystems, DNA, Polymerase chain reaction, Dog, CDMO, CAR, Severe acute respiratory syndrome coronavirus 2, Veterinary medicine, Safety, Therapy, Applied DNA Sciences, Manuscript, Vaccine, PCR, LNP

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .
  • An initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022.
  • The study demonstrated safety and immunogenicity of a linearDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines.
  • Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort, which induced robust neutralizing antibody titers and cellular immune responses.

ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Genetics, Conference, RNA transfection, Recode, Therapy, Pharmaceutical industry, Antibiotics

ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a company overview at 9:00 a.m. PT on Tuesday, January 10, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.

Key Points: 
  • ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a company overview at 9:00 a.m. PT on Tuesday, January 10, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.

Cancer Gene Therapy Global Market Report 2022: 20% Annual Growth Driven by Rising Demand and Increasing Prevalence of Cancer - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Genetics, Health, Oncology, Government, Cancer, Prostate cancer, Region, Merck & Co., RNA transfection, Research, Projection, Neoplasm, USD, Risk, Immunotherapy, Bluebird bio, Disease, Patient, Oncolytic virus, HCRI, FDA, Immune system, Dove Medical Press, National Cancer Institute, Incidence, RNA, Fine chemical, Vaccine, Pharmaceutical industry

The "Cancer Gene Therapy Market by Therapy, by End-user, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Gene Therapy Market by Therapy, by End-user, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Rising demand for gene therapy and a surge in the number of cancer patients worldwide are projected to drive the market growth in near future.
  • However, unfavourable immune response and high price of gene therapy is predicted to limit market growth are expected to restrain the market growth.
  • The increasing demand for novel therapeutic medications that can be useful for cancer therapy is anticipated due to the rising incidence of cancer cases.

Global Pharmaceutical Lipid-based Nanoparticles Research Report 2022: Focus on Pre-clinical and Clinical Advancements - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 22, 2022
Health, Pharmaceutical, Clinical, Cancer, Nutraceutical, Organic acid, Plasmid, Nanomedicine, Traffic barrier, Food, RNA transfection, Research, Neurodegeneration, COVID-19, Cosmetics, Phospholipid, Liposome, Pharmaceutical industry, Lipid, BBB, FDA, Therapy, Brain, Sirna, Nanotechnology, Food and Drug Administration, Vaccine, LNP

The "Lipid-based Nanoparticles for the Pharmaceutical Industry: Pre-clinical and Clinical Advancements" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lipid-based Nanoparticles for the Pharmaceutical Industry: Pre-clinical and Clinical Advancements" report has been added to ResearchAndMarkets.com's offering.
  • This study offers an in-depth analysis of the current research and industrial developments in use of lipid-based nanoparticles.
  • Among the different nanotechnology-based innovations, lipid-based nanoparticles such as liposomes and lipid nanoparticles (LNPs) show great promise across multiple therapies.
  • This research answers the following questions:
    What are the current research advancements in use of LNPs for therapeutic and vaccine delivery?